Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 19 | 39 | 21 | 4 | 30 | 105 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | 7 | 4 | 1 | 5 | 17 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | 2 | — | — | 2 |
Gynecomastia | D006177 | — | N62 | — | 1 | 1 | — | — | 2 |
Recurrence | D012008 | — | — | — | — | 1 | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 3 | 3 | — | — | 1 | 6 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 4 | — | — | — | 6 |
Adenocarcinoma | D000230 | — | — | 1 | 4 | — | — | — | 5 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 3 | — | — | 1 | 4 |
Carcinoma | D002277 | — | C80.0 | 1 | 2 | — | — | 1 | 4 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 2 | — | — | 1 | 4 |
Non-small-cell lung carcinoma | D002289 | — | — | 3 | 1 | — | — | — | 3 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 2 | — | — | — | 3 |
Colorectal neoplasms | D015179 | — | — | 2 | 1 | — | — | — | 2 |
Lung neoplasms | D008175 | — | C34.90 | 2 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Pharmacological phenomena | D000069437 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
Coronary disease | D003327 | — | — | — | — | — | — | 1 | 1 |
Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 1 | 1 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 1 | 1 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 1 | 1 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
Disease susceptibility | D004198 | — | — | — | — | — | — | 1 | 1 |
Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | — | — | 1 | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | — | 1 | 1 |
Drug common name | Aglatimagene besadenovec |
INN | aglatimagene besadenovec |
Description | Aglatimagene besadenovec is a gene pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Gene |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3544993 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 5Z72SSS34W (ChemIDplus, GSRS) |